CBIO

Crescent Biopharma (CBIO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

SEC Filings

BlackRock Reports 5.6% Stake In Crescent Biopharma, 2,075,291 Shares

The asset manager certified it holds the shares in the ordinary course of business, not to influence control of the cancer-drug developer.

Earnings

Crescent Biopharma Targets First-Quarter 2027 Data For CR-001 And Early-2028 Phase 3 Start

An 8-K sets readout timing from early 2027 and reports FDA clearance to proceed with a second drug, CR-002.